Recombinant Anti-CD3 x Anti-CD44 Bispecific Antibody (Tandem scFv) is designed to be expressed as a scFv from an anti-CD3 antibody variable domains fused with a scFv from an anti-CD44 antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can retarget T cells to tumor cells. It is designed for the research of Glioblastoma; Squamous cancer therapy.